Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03922204 · ClinicalTrials.gov registry record · Phase 1
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
A Phase 1 study, sponsored by Merus B.V..
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT03922204 is a Phase 1 study that has completed, run by Merus B.V.. The registered enrollment target is 72 participants.
The verdict
NCT03922204, a Phase 1 study, has completed, sponsored by Merus B.V..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This is an open-label, non-randomized, Phase 1 study to determine the safety, tolerability, and preliminary efficacy of MCLA-145 in adult patients with advanced metastatic solid tumors or B-cell lymphomas. The study will be conducted in 2 parts.
Interventions
- DRUG Pembrolizumab (Keytruda)
- DRUG MCLA-145
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2019-05-08 |
| Est. Completion | 2024-11-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03922204
The ClinicalTrials.gov registry entry for NCT03922204 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merus B.V., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab (Keytruda) is the first listed.
NCT03922204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03922204 about?
NCT03922204 is a clinical study titled "A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies". This is an open-label, non-randomized, Phase 1 study to determine the safety, tolerability, and preliminary efficacy of MCLA-145 in adult patients with advanced metastatic solid tumors or B-cell lymphomas. The study will be conducted in 2 parts.
What is the current status of trial NCT03922204?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2019-05-08. Estimated completion is 2024-11-07.
What interventions are being tested in trial NCT03922204?
The interventions under investigation include: Pembrolizumab (Keytruda) (DRUG), MCLA-145 (DRUG).
Who is sponsoring clinical trial NCT03922204?
This trial is sponsored by Merus B.V., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.